New cocktail aims to tackle stomach cancer relapse
NCT ID NCT07669740
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of three drugs—sintilimab, ramucirumab, and paclitaxel—in 30 adults with HER2-negative stomach cancer that came back during or within 6 months of finishing adjuvant therapy. The main goal is to see how many patients' tumors shrink significantly. Researchers will also look for biomarkers to personalize future treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sintilimab, ramucirumab, and paclitaxel
What this could lead to
If it works, this could offer a new treatment option for gastric cancer that comes back quickly after standard therapy, potentially shrinking tumors and delaying progression.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug combination can cause serious side effects, and there is no guarantee it will work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••